



Yang (Aaron) Gu

Shanghai

+86 21 6080 0505
aaron.gu@hankunlaw.com

PRACTICE AREAS

- Life sciences and healthcare
- Corporate compliance
- Foreign direct investment
- Mergers and acquisitions
- General corporate

PROFESSIONAL EXPERIENCE

Mr. Gu practiced law with Covington & Burling LLP in Shanghai, Washington D.C., and New York for approximately eight years before joining Han Kun Law Offices in 2022. Prior to Covington, Mr. Gu also interned and worked for many years in the New York office of Jun He Law Offices and the Shanghai office of Advokatfirman Vinge KB.

Mr. Gu focuses on corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities. Specifically, Mr. Gu's services cover a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has been interviewed by Blue View, Caixin, China Business Network, Dutch Financial Daily, Faxian Magazine, Healthcare Executive, International Pharmaceutical News for China, Jiemian, Thomson Reuters and other media (in alphabetical order).

Mr. Gu has extensive experience representing different types of companies in the life sciences industries, including but not limited to multinational pharmaceutical companies such as Abbott, AbbVie, Amgen, Astellas, AstraZeneca, BioNTech, bioMérieux, Eli Lilly, GlaxoSmithKline, Illumina, Johnson & Johnson, Merck, Merck Sharp & Dohme, Sanofi, and Viatrix, biotech companies such as BeiGene, Connect Biopharma, Henlius, Huadong Medicine, Innovent, Legend Biotech, WuXi Biologics and Zai Lab, leading Internet companies such as Baidu, Tencent and ByteDance as well as investment institutions such as C Capital, CBC Group, IDG Capital, Matrix Partners, OrbiMed, Qiming Venture Partners, Sequoia Capital and Tiantu Capital (in alphabetical order).

EDUCATION

Mr. Gu received a Bachelor of Laws and a Bachelor of Economics from East China University of Political Science and Law and Shanghai University of International Business and Economics, respectively. He also received an LL.M. degree from the New York University School of Law.

QUALIFICATIONS

Member of the PRC Bar

Member of the New York State Bar

HONORS AND AWARDS

Legalband, Top 15 Lawyers, Healthcare & Pharmaceuticals (2022)

Mondaq, Thought Leadership Award (2023)

The Legal 500, Life Sciences and Healthcare, Key Lawyers (2024)

SOCIAL RESPONSIBILITIES

Committee Member of the NYU Alumni Club in Shanghai

Special Consultant of the Science and Technology Innovation Board of the Pujiang Capital Market Training Base

PUBLICATIONS

The China chapter of Editions 7, 8, 9, and 10 (2019-2022) of The Life Sciences Law Review;

The China chapter of Editions 6 and 7 (2022-2023) of The Healthcare Law Review;

Chambers Life Sciences Global Practice Guide (2022-2023); and

Chambers Healthcare: Medical Devices Global Practice Guide (2023).

WORKING LANGUAGES

Chinese, English



顾泱

上海

+86 21 6080 0505
aaron.gu@hankunlaw.com

业务领域

- 生命科学与健康
- 公司合规
- 外商直接投资
- 兼并和收购
- 一般公司事务

工作经历

顾律师在 2022 年加入汉坤律师事务所之前，曾在美国科文顿·柏灵律师事务所上海、华盛顿和纽约办公室工作近八年。在此之前，他还曾于君合律师事务所纽约办公室和瑞典维格律师事务所驻上海代表处工作多年。

顾律师专注于生命科学、生物医药及医疗健康领域的公司、监管合规以及交易业务，包括生物安全法及人类遗传资源、临床试验、产品上市许可、GxP 合规、跨境医药许可及商业化合作（License-in/out），生命科学行业内投融资及兼并收购、外商投资、对外投资等事宜中的行业监管相关问题等，并就中国药品监督管理局及其他政府机关颁布的法规征求意见稿为客户提供分析并起草相关建议函。具体产品涵盖药品（生物药和化学药）、医疗器械、体外诊断试剂（IVD）、化妆品、普通食品、特殊食品（保健食品、特殊医学用途配方食品和婴幼儿配方食品）、兽药、宠物食品/饲料等。顾律师曾多次接受《财新》《第一财经》《E 药经理人》《发现杂志社》《国际医药商情》《荷兰金融日报》《界面新闻》《深蓝观》《汤森路透》等媒体采访（按字母顺序排列，排名不分先后）。

顾律师具有代表生命科学领域内不同类型企业的丰富经验，包括但不限于艾伯维、安进、阿斯泰来、阿斯利康、拜恩泰科、葛兰素史克、晖致、礼来、默克、默沙东、强生、生物梅里埃、赛诺菲、雅培、因美纳以及百济神州、复宏汉霖、华东医药、康乃德、南京传奇、信达生物、药明生物、再鼎医药等跨国药品企业与创新药企业，百度、腾讯、字节跳动等互联网头部企业，C Capital、CBC Group、IDG 资本、奥博资本、红杉资本、经纬创投、启明创投、天图投资等投资机构（按字母顺序排列，排名不分先后）。

教育背景

顾律师分别从华东政法大学和上海对外经贸大学获得法学学士和经济学学士学位，并于美国纽约大学法学院（NYU School of Law）获得法学硕士学位。

执业资格

中华人民共和国律师执业资格
美国纽约州律师执业资格

荣誉与奖项

Legalband, 医疗健康与医药领域, 15 强律师 (2022)

Mondaq, 意见领袖奖 (Thought Leadership Award) (2023)

The Legal 500, 医疗与生命科学, 推荐律师 (2024)

社会任职

纽约大学上海校友会委员会委员

浦江资本市场实训基地科创服务专委会特邀顾问

最近出版物

《生命科学法律评论》(第 7-10 版, 2019-2022 年) 和《全球医疗卫生法律评论》(第 6-7 版, 2022-2023 年) 的中国章节,《钱伯斯生命科学全球实务指南》(2022-2023 年) 中国篇, 及《钱伯斯医疗健康: 医疗器械全球实务指南》(2023 年)

工作语言

中文、英文